Anavex Life Sciences Corp (AVXL)

[sokol]

Anavex “has surpassed by 50% the company’s original enrollment target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study in Rett syndrome.” So, Anavex has more patients in the study in the United States than it originally planned to enroll here in the U.S.? Exceeding its goal in enrollment is a newsworthy event, but I am not sure what this means. Where do we stand on Rett enrollment elsewhere?